FDA-cleared profile

FETOLY

Diagnoly · Ultrasound · FDA-cleared (510(k))

Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.

Clinical role
FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
Images and patients
Ultrasound · Fetal heart and fetal brain
Key limitation
Keep in mind: The output is a concurrent reading aid; gestational-age, acquisition, patient, and professional-review requirements in the exact labeling govern use.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetal heart and fetal brain Input: Ultrasound echo data acquired with the supported transducers, exam modes, and labeled patient or anatomy scope.
  • Who uses it?Intended users: Qualified healthcare professionals interpreting fetal ultrasound.
  • What does the software produce?Output: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.
  • What is its most important limitation?Key limitation: The output is a concurrent reading aid; gestational-age, acquisition, patient, and professional-review requirements in the exact labeling govern use.

Clinical takeaway. Clinical role: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports two standalone performance studies with a 2+1 ground truth procedure as reference standard. Completeness: 5,554 images across 750 patient cases from 7 clinical sites (United States and France); view detection mean sensitivity 96% (Bootstrap CI 0.954-0.966) and mean specificity 99.5% (0.994-0.996). Measurement: 6,024 images across 441 patient cases from 6 clinical sites; all measurements met limits-of-agreement acceptance criteria. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Ultrasound echo data acquired with the supported transducers, exam modes, and labeled patient or anatomy scope.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Professional healthcare facilities, including hospitals, clinics, and clinical point-of-care settings, as applicable to the labeled exam.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified healthcare professionals interpreting fetal ultrasound.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The output is a concurrent reading aid; gestational-age, acquisition, patient, and professional-review requirements in the exact labeling govern use.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports two standalone performance studies with a 2+1 ground truth procedure as reference standard. Completeness: 5,554 images across 750 patient cases from 7 clinical sites (United States and France); view detection mean sensitivity 96% (Bootstrap CI 0.954-0.966) and mean specificity 99.5% (0.994-0.996). Measurement: 6,024 images across 441 patient cases from 6 clinical sites; all measurements met limits-of-agreement acceptance criteria. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Diagnoly conducted two standalone performance testing: - One for the completeness functionality of FETOLY; - One for the measurement functionality of FETOLY" … "FETOLY-COMPLETENESS performance study This study was done on a dataset of 5,554 fetal ultrasound images across 750 patient cases, including full examination still images, cardiac/brain clip frames and full examination video frames from 7 clinical sites in the United States and France.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports two standalone performance studies with a 2+1 ground truth procedure as reference standard. Completeness: 5,554 images across 750 patient cases from 7 clinical sites (United States and France); view detection mean sensitivity 96% (Bootstrap CI 0.954-0.966) and mean specificity 99.5% (0.994-0.996). Measurement: 6,024 images across 441 patient cases from 6 clinical sites; all measurements met limits-of-agreement acceptance criteria. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Diagnoly conducted two standalone performance testing: - One for the completeness functionality of FETOLY; - One for the measurement functionality of FETOLY" … "FETOLY-COMPLETENESS performance study This study was done on a dataset of 5,554 fetal ultrasound images across 750 patient cases, including full examination still images, cardiac/brain clip frames and full examination video frames from 7 clinical sites in the United States and France.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Standalone mean sensitivity on the completeness dataset (5,554 images, 750 patient cases): fetal heart and brain view detection 96% (Bootstrap CI 0.954-0.966); 52 fetal heart quality criteria 94.6% (Bootstrap CI 0.939-0.952).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Diagnoly conducted two standalone performance testing: - One for the completeness functionality of FETOLY; - One for the measurement functionality of FETOLY 7.2.1 FETOLY-COMPLETENESS performance study This study was done on a dataset of 5,554 fetal ultrasound images across 750 patient cases," … "Automatic detection of fetal heart and brain views ‘Abdomen’, ‘Four chamber’, ‘LVOT’, ‘RVOT’, ‘Three Vessels’, Transventricular’, ‘Transcerebellar’, ‘Transthalamic’ and ‘Sagittal/profile’: o mean sensitivity of 96% with a Bootstrap CI of (0.954-0.966);". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Reported specificity
Standalone mean specificity on the completeness dataset (5,554 images, 750 patient cases) for fetal heart and brain view detection: 99.5% (Bootstrap CI 0.994-0.996); for 52 fetal heart quality criteria: 99.4% (Bootstrap CI 0.994-0.995).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Diagnoly conducted two standalone performance testing: - One for the completeness functionality of FETOLY; - One for the measurement functionality of FETOLY 7.2.1 FETOLY-COMPLETENESS performance study This study was done on a dataset of 5,554 fetal ultrasound images across 750 patient cases," … "Automatic detection of fetal heart and brain views ‘Abdomen’, ‘Four chamber’, ‘LVOT’, ‘RVOT’, ‘Three Vessels’, Transventricular’, ‘Transcerebellar’, ‘Transthalamic’ and ‘Sagittal/profile’: o mean sensitivity of 96% with a Bootstrap CI of (0.954-0.966); o mean specificity of 99.5% with a Bootstrap CI of (0.994-0.996).". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Fetal ultrasound completeness study dataset

750 patient cases

  • EndpointCases represented in the reported completeness dataset
  • PopulationFetal ultrasound cases spanning the labeled second- and third-trimester workflow
  • Tested versionExact FDA submission release; version not separately stated in the public decision material

K251368 FDA evidence package for FETOLY

  • DesignManufacturer-submitted standalone performance testing for fetal ultrasound completeness and measurement functions; not independent clinical validation.
  • PopulationFetal ultrasound images and sequences in the exact FETOLY validation package.
  • Scopeexact submission
  • Tested versionExact FDA submission release; version not separately stated in the public decision material
  • Samplen=750
  • IndependenceSponsor or vendor study

K251368

Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K251368 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, dental, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Reviewed CMS material is not a product-specific price or coverage determination; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Ultrasound echo data acquired with the supported transducers, exam modes, and labeled patient or anatomy scope.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K251368: FETOLY

  2. Routing

    Source context, not route validation: The software is installed on hardware connected to an ultrasound machine through HDMI; exact data flow, export, and local interface behavior require acceptance.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K251368: FETOLY

  3. AI processing

    Source context, not route validation: The exact FDA package describes Fetoly software installed on a hardware device connected to an ultrasound machine through an HDMI connection, receiving ultrasound images captured by the connected machine in real time. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "To utilize Fetoly, the software needs to be installed on a hardware device which is connected to an Ultrasound Machine through an HDMI connection." … "The software receives ultrasound images captured by the connected Ultrasound Machine in real-time.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K251368: FETOLY

  4. Returned objects

    Source context, not route validation: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K251368: FETOLY

  5. Viewer/worklist/report

    Unresolved route: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K251368: FETOLY

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Fetoly software installed on a hardware device connected to an ultrasound machine through an HDMI connection, receiving ultrasound images captured by the connected machine in real time. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "To utilize Fetoly, the software needs to be installed on a hardware device which is connected to an Ultrasound Machine through an HDMI connection." … "The software receives ultrasound images captured by the connected Ultrasound Machine in real-time.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The software is installed on hardware connected to an ultrasound machine through HDMI; exact data flow, export, and local interface behavior require acceptance.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K251368 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

The software is installed on hardware connected to an ultrasound machine through HDMI; exact data flow, export, and local interface behavior require acceptance.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The output is a concurrent reading aid; gestational-age, acquisition, patient, and professional-review requirements in the exact labeling govern use.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the evidence set; productivity or value claims require local evidence.

Lifecycle monitoring

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.

exact submission · checked 2026-09-04

Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251368
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Fetal heart and fetal brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-09-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission

    Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K251368: FETOLY

    U.S. Food and Drug Administration - Published 2025-09-12 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K251368 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K240553

LVivo Software Application

DiA Imaging Analysis Ltd.

Non-invasive processing of ultrasound images to detect, measure, and calculate relevant medical parameters of structures and function in patients with suspected disease, with Quality Score feedback.

Modality
Ultrasound
Anatomy
Heart and cardiovascular structures, especially the left and right ventricles; a bladder-volume module is also described
Decision
2024-10-04
FDA-cleared K222970

LVivo IQS

DiA Imaging Analysis Ltd

Non-invasive processing of ultrasound images to detect, measure, and calculate medical parameters of structures and function in patients with suspected disease, with Quality Score feedback; the submitted IQS module provides real-time quality scoring for the left ventricle from the four-chamber apical view.

Modality
Ultrasound
Anatomy
Heart; left ventricle from the four-chamber apical view
Decision
2023-02-01

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history